Targeted Immunotherapy for Pre-Invasive High Risk Human Papillomavirus Disease

Please arrive 5 minutes before the Seminar begins to gain building access

High risk human papillomaviruses (hrHPV) are responsible for over 0.5 million cases of cervical cancer and 70,000 anogenital and oropharyngeal cancers annually. Invasive lesions represent the end stage of a minority of persistent infections that cause progressive dysplasia over many years. Licensed preventive vaccines do not prevent disease in women with pre-existing hrHPV infection. I will discuss progress towards development of therapeutic vaccines that harness cell-mediated immune responses to eliminate pre-invasive lesions and persistent infections.